Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases
- 22 May 2012
- journal article
- Published by Springer Science and Business Media LLC in Clinical Rheumatology
- Vol. 31 (8), 1223-1230
- https://doi.org/10.1007/s10067-012-1998-0
Abstract
Macrophage activation syndrome (MAS) belongs to secondary hemophagocytic lymphohistiocytosis (HLH) syndrome. It is usually associated with rheumatic diseases. We retrospectively reviewed our hospital’s medical records of 102 HLH/MAS patients from the past 20 years. Demographics, clinical data, treatment, and outcomes were analyzed. Among 102 patients, eight patients with underlying juvenile systemic lupus erythematous (two patients), mixed connective tissue disease (one patient), primary anti-phospholipid syndrome (one patient), and systemic type juvenile rheumatoid arthritis (sJRA; four patients) with 13 episodes of MAS were studied. Clinical manifestations of MAS included fever (100 %), hepatosplenomegaly (77 %), lymphadenopathy (38 %), skin rash (62 %), and neurological involvement (31 %). Laboratory features included leukopenia (54 %), anemia (46 %), thrombocytopenia (77 %), jaundice (27 %), hypofibrinogenemia (40 %), decreased erythrocyte sedimentation rate (67 %), and elevated liver enzymes (77 %), lactate dehydrogenase (100 %), ferritin (88 %), triglycerides (91 %), C-reactive protein (85 %), plasma D-dimer (50 %), and hemophagocytosis in bone marrow (83 %). The Epstein–Barr virus and adenovirus infection triggered MAS in two patients with sJRA. Methylprednisolone pulse therapy was effective in two out of three patients, and high-dose intravenous immunoglobulin (IVIG) was effective in two out of six patients. Patients with sJRA responded well to corticosteroids and cyclosporine. Complications included opportunistic infection with Pneumocystis jiroveci, multiple organ failure, and intensive care unit myopathy. The mortality rate was one out of eight (12.5 %). Our results showed that MAS could be fatal and complicate various pediatric autoimmune diseases. It generally has a good response to corticosteroids and IVIG. Prompt recognition and timely treatment can result in good outcomes.This publication has 42 references indexed in Scilit:
- Monitoring serum IL-18 levels is useful for treatment of a patient with systemic juvenile idiopathic arthritis complicated by macrophage activation syndromePediatric Rheumatology, 2011
- Rapid and Sustained Remission of Systemic Juvenile Idiopathic Arthritis-Associated Macrophage Activation Syndrome Through Treatment With Anakinra and CorticosteroidsJCR: Journal of Clinical Rheumatology, 2011
- Proposed disease activity criteria for mixed connective tissue diseaseLupus, 2009
- Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13‐4 polymorphismsArthritis & Rheumatism, 2008
- Successful treatment of cytomegalovirus-associated hemophagocytic syndrome by intravenous immunoglobulinsAmerican Journal of Hematology, 2008
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritisThe Journal of Pediatrics, 2005
- Perforin Gene Defects in Familial Hemophagocytic LymphohistiocytosisScience, 1999
- Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporineThe Journal of Pediatrics, 1996
- Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: Possible relationship to drugs or infectionThe Journal of Pediatrics, 1985